Pilocytic astrocytoma (PA) is emerging as a tumor entity with dysregulated RAS/RAF/MEK/ERK signaling. In this study, we report the identification of a novel recurrent BRAF insertion (p.V504_R506dup) in five PA cases harboring exclusively this somatic tandem duplication. This recurrent alteration leads to an addition of three amino acids in the kinase domain of BRAF and has functional impact on activating MAPK phosphorylation. Importantly, we show that this mutation confers resistance to RAF inhibitors without changing effectiveness while downstream MEK inhibitors remain effective. Our results further emphasize the importance of BRAF alterations in PA and the need to characterize them in a given tumor as this can affect therapeutic strategies and their potential use as tumor marker in molecular diagnostics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484687 | PMC |
| http://dx.doi.org/10.1038/s41388-018-0623-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Papillary thyroid carcinoma with BRAF , TERT promoter C228T and insertional mutation: A case report.
Asian J Surg
November 2024
Department of Pathology, Affiliated Hospital of Jining Medical University, Jining, Shandong province, 272029, China. Electronic address:
The value of NGS-based multi-gene testing for differentiation of benign from malignant and risk stratification of thyroid nodules.
Front Oncol
November 2024
Center for Clinical Genetics and Genomics, Dian Diagnostics Group Co., Ltd., Hangzhou, China.
Background: Fine-needle aspiration (FNA) biopsy is typically used in conjunction with cytopathologic evaluation to differentiate between benign and malignant thyroid nodules. Even so, the cytology results for 20-30% of thyroid nodules are indeterminate. This study sought to evaluate the usefulness of next-generation sequencing (NGS)-based multi-gene panel testing for risk stratification and the differentiation of benign from malignant thyroid nodules.
View Article and Find Full Text PDFReal-World Study on Implementation of Genomic Tests for Advanced Lung Adenocarcinoma in Brazil.
JCO Glob Oncol
November 2024
Oncoclínicas & CO-Medica Scientia Innovation Research (MedSir), São Paulo, Brazil.
Article Synopsis
- The study explores challenges in lung cancer biomarker testing due to tissue inadequacy and operational issues, implementing a tailored molecular testing approach in Brazil.
- From 1,272 lung cancer samples analyzed, a significant percentage were ineligible for testing due to insufficient tissue quality or quantity, with specific mutations and alterations being most commonly observed.
- Results suggest that while non-NGS tests provided some diagnostic information, a substantial portion of patients could only access reduced molecular testing coverage, impacting the detection of actionable cancer drivers.
ASPYRE-Lung: validation of a simple, fast, robust and novel method for multi-variant genomic analysis of actionable NSCLC variants in FFPE tissue.
Front Oncol
September 2024
Biofidelity Ltd., Cambridge, United Kingdom.
Article Synopsis
- ASPYRE Technology
- : ASPYRE (Allele-Specific PYrophosphorolysis REaction) was created to provide a quick, affordable, and effective genomic testing method for cancer, specifically non-small cell lung carcinoma, assessing 114 variants in 11 genes simultaneously from tumor samples.
- Testing and Results
- : When tested on various lung tissue samples, ASPYRE-Lung showed a detection sensitivity of ≤ 3% for single nucleotide variants, with perfect specificity and high analytical accuracy, matching expected results without false positives.
- Ease of Use
- : The assay requires minimal steps and standard lab equipment, with data analysis supported by a cloud-based algorithm, making it a potentially transformative tool for
Clinical Utility of Circulating Tumor DNA for Detecting Lung Cancer Mutations by Targeted Next-Generation Sequencing With Insufficient Tumor Samples.
J Clin Lab Anal
October 2024
Department of Molecular Diagnostics, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong Province, China.
Background: Circulating tumor deoxyribonucleic acid (ctDNA) is increasingly applied in clinical practice. This study aimed to explore clinical utility of a minimal invasive and sensitive way of ctDNA for next-generation sequencing in non-small cell lung cancer (NSCLC) with inadequate tumor samples.
Methods: Targeted DNA sequencing was performed on tissue biopsies and matched plasma samples from 60 patients with NSCLC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!